Literature DB >> 20122944

Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature.

S Murray1, H Linardou, G Mountzios, M Manoloukos, S Markaki, E Eleutherakis-Papaiakovou, M A Dimopoulos, C A Papadimitriou.   

Abstract

OBJECTIVE: The rarity of uterine sarcomas along with their pathological and molecular heterogeneities render their study particularly challenging. We evaluated a panel of somatic mutations principally centering on the tyrosine kinase gene family and their downstream signaling cascades in an attempt to identify potential candidate markers that may assist in diagnostic or therapeutic decisions in these tumors.
METHODS: We performed mutational analysis of 20 exons from 9 genes (EGFR, CDKN2A, MET, KIT, RAS, BRAF, PI3KCA, HER-2 and PDGFR-alpha) on biopsy material from 25 patients who underwent primary surgery for uterine sarcoma between October 1995 and October 2003. Due to the limited number of studies conducted we have also undertaken a literature review of somatic mutations in uterine sarcomas.
RESULTS: A total of 3 different somatic mutations were identified: one KRAS (codon G12D) in a carcinosarcoma and two exon 20 PI3KCA mutations (H1047R and H1047Y) both in carcinosarcomas. Mutational status of all mutations was confirmed using germline DNA extracted from peripheral blood. Consistent with the literature data, no other mutations regarding the rest of the genes of the panel were identified. Due to the low number of somatic mutations in our series, we did not perform further clinicopathological correlations.
CONCLUSION: The absence of somatic mutations in the majority of genes that are considered critical in neoplastic transformation hampers the identification of potential therapeutic targets in patients with uterine sarcoma. Copyright 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20122944     DOI: 10.1016/j.mrfmmm.2010.01.019

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  6 in total

1.  The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.

Authors:  Matthieu Le Gallo; Meghan L Rudd; Mary Ellen Urick; Nancy F Hansen; Maria J Merino; David G Mutch; Paul J Goodfellow; James C Mullikin; Daphne W Bell
Journal:  Cancer       Date:  2017-09-21       Impact factor: 6.860

2.  Use of mutation profiles to refine the classification of endometrial carcinomas.

Authors:  Melissa K McConechy; Jiarui Ding; Maggie Cu Cheang; Kimberly Wiegand; Janine Senz; Alicia Tone; Winnie Yang; Leah Prentice; Kane Tse; Thomas Zeng; Helen McDonald; Amy P Schmidt; David G Mutch; Jessica N McAlpine; Martin Hirst; Sohrab P Shah; Cheng-Han Lee; Paul J Goodfellow; C Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2012-07-18       Impact factor: 7.996

3.  Dual Pten/Tp53 suppression promotes sarcoma progression by activating Notch signaling.

Authors:  Maria V Guijarro; Sonika Dahiya; Laura S Danielson; Miguel F Segura; Frances M Vales-Lara; Silvia Menendez; Dorota Popiolek; Khushbakhat Mittal; Jian Jun Wei; Jiri Zavadil; Carlos Cordon-Cardo; Pier Paolo Pandolfi; Eva Hernando
Journal:  Am J Pathol       Date:  2013-06       Impact factor: 4.307

4.  Endometrial stromal tumors: immunohistochemical and molecular analysis of potential targets of tyrosine kinase inhibitors.

Authors:  Carmen Balañá; Enrique de Álava; Ruth Sardinha; Teresa Hernández; Susana Fraile; Francesc Tresserra; August Vidal; Maria Carmén Gómez; Aurora Astudillo; Nieves Hernández; Javier Saenz de Santamaría; Jaume Ordi; Luis Gonçalves; Rafael Ramos
Journal:  Clin Sarcoma Res       Date:  2013-03-07

Review 5.  Potential Therapeutic Targets in Uterine Sarcomas.

Authors:  Tine Cuppens; Sandra Tuyaerts; Frédéric Amant
Journal:  Sarcoma       Date:  2015-10-21

6.  Identification of Somatic Genetic Alterations Using Whole-Exome Sequencing of Uterine Leiomyosarcoma Tumors.

Authors:  Lihua Chen; Jiajia Li; Xiaohua Wu; Zhong Zheng
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.